Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET
Company Participants
Clint Tomlinson - Investor Relations
Christopher Missling - President & Chief Executive Officer
Sandra Boenisch - Principal Financial Officer.
Conference Call Participants
Yun Zhong - BTIG
Pete Stavropoulos - Cantor
Operator
Welcome to the Anavex Life Sciences Fiscal 2022 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator instructions] Please note that this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company's filings with the SEC. This includes, without limitation, the company's Forms 10-K and 10-Q, which identify the specific factors that may cause actual results or even events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital and maintenance of intellectual property rights.
And with that, I would like to turn the call over to Dr. Missling.
Christopher Missling
Thank you, Clint. We appreciate everyone joining us on today's conference call to review our most recently reported financial results and to provide a business update. We are pleased with the continued advancement regarding our lead product candidate, ANAVEX 2-73in ultimate disease and drag syndrome, as we maintain our attention on execution across each of our clinical programs and overall business operations.
In the second half of 2022, we are expecting two pivotal top line results readouts, including top line results from the randomized placebo-controlled 2b/3 study ANAVEX 2-73-AD-004 for the treatment of Alzheimer’s and from the randomized placebo-controlled excellent Phase 2/3 study ANAVEX 2-73-RS-003 for the treatment of pediatric patients with Rett syndrome. Next month, ANAVEX will host our R&D Day for investors and analysts on Tuesday, June 21, 2022. This R&D day will include presentations from the company's leadership team with a focus on the company's clinical development pipeline. Additional details will follow closer to the event.